Accelerating Pre-Clinical Large-Molecule Screening with an Integrated DMPK/ADME Approach
In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.
In this webinar, BioDuro will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:
- LC-MS/MS, ELISA, and Gyrolab as comparable bioanalytical methods for ADC and antibody PK analysis
- Transgenic mouse PK as a rapid screening approach
- ADME screening strategies for peptides, linkers, and payloads in ADC programs.
These case studies demonstrate how an integrated DMPK/ADME platform can accelerate preclinical screening and improve decision-making for early-stage large-molecule programs. While bioanalysis of biologics and conjugated therapeutics presents unique challenges due to matrix complexity, molecular heterogeneity, and evolving analytical requirements, innovative bioanalytical strategies can generate robust, reliable data that enable confident candidate selection and successful program progression.
What you will learn:
- Understand the strengths and applications of LC-MS/MS, ELISA, and Gyrolab for consistent pharmacokinetic analysis of antibodies and ADC
- Learn how transgenic mouse pharmacokinetic models can serve as a rapid and efficient approach for early candidate screening
- Explore ADME screening strategies for peptides, linkers, and payloads to support the discovery and optimization of ADC programs
Hosted by:
